{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:15:01Z","timestamp":1785798901241,"version":"3.56.0"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2018SK52108"],"award-info":[{"award-number":["2018SK52108"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To compare the response and safety of Ixazomib\/Lenalidomide\/Dexamethasone (IRd) and Bortezomib\/Lenalidomide\/Dexamethasone (VRd) treatment in newly diagnosed multiple myeloma (MM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single\u2010center retrospective analysis in Xiangtan Central Hospital. A total of 52 newly diagnosed MM patients from June 2019 to June 2021 were enrolled and divided into the IRd (<jats:italic>n<\/jats:italic>\u00a0=\u00a021) and VRd (<jats:italic>n<\/jats:italic>\u00a0=\u00a031) groups. After 4\u00a0cycles of chemotherapy, the best response and adverse events were recorded. Moreover, the progression\u2010free survival (PFS) and overall survival (OS) were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients in IRd group and VRd group showed similar PFS (Log\u2010rank <jats:italic>p<\/jats:italic>\u00a0=\u00a00.70), OS (Log\u2010rank <jats:italic>p<\/jats:italic>\u00a0=\u00a00.61) and overall response rate (83.87% vs 90.48%, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.803). In addition, patients in VRd group showed lower Eastern Cooperative Oncology Group scores (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.047), and higher incidence of peripheral sensory neuropathy (0.00% vs 19.35%, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.032) than that of patients in IRd group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared to VRd regimen, IRd had the similar efficacy, better safety, and may be more convenient for patients with poor basic condition for newly diagnosed MM. This study provides an insight for physicians to use IRd as first\u2010line treatment in MM.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.5198","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T07:54:43Z","timestamp":1662105283000},"page":"2937-2944","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China\u2014Compared with bortezomib\/lenalidomide\/dexamethasone"],"prefix":"10.1002","volume":"12","author":[{"given":"Zhongjun","family":"Huo","sequence":"first","affiliation":[{"name":"Department of Hematology Central Hospital of Xiangtan  XiangTan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology Central Hospital of Xiangtan  XiangTan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Central Hospital of Xiangtan  XiangTan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2946-7686","authenticated-orcid":false,"given":"Zimian","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology Central Hospital of Xiangtan  XiangTan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00527-y"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26161"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01433-9"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01197-w"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205084"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01162-7"},{"key":"e_1_2_12_9_1","unstructured":"https:\/\/www.nccn.org\/guidelines\/guidelines\u2010detail?category=1&id=1445."},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092540"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01317-y"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14996"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720261"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.10139"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010350"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.015370"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-021-00863-2"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.055953"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.712070"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21386-y"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101611"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0298-1"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0702-1"},{"issue":"5","key":"e_1_2_12_27_1","first-page":"5248","article-title":"A comparison of the efficacy and safety of ixazomib and lenalidomide combined with dexamethasone in the treatment of multiple myeloma","volume":"13","author":"Zheng Z","year":"2021","journal-title":"Am J Transl Res"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.011"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14125"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0548-5"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03981-z"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25134"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00972"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0384-1"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15394"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008787"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4313"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5198","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.5198","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T08:22:57Z","timestamp":1732522977000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/cam4.5198"],"URL":"https:\/\/doi.org\/10.1002\/cam4.5198","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"assertion":[{"value":"2021-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}